CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $203.5M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 2.58: grey zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
203.50MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.8450xvs all stocks
52-Week Change
-70.42%vs all stocks
Market Capitalization
203.50MUSDvs all stocks (USD)
Enterprise Value
33.25MUSDvs all stocks (USD)
Forward P/E
-2.10xvs Biotechnology peers
Price to Book (MRQ)
1.23xvs Biotechnology peers
Enterprise to EBITDA
-0.4100xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-33.03%vs Biotechnology peers
Return on Equity (TTM)
-56.66%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 26, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-81.01MUSDvs all stocks (USD)
Net Income (TTM)
-73.45MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-56.11MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-31.36MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 26, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-72.84MUSDvs all stocks (USD)
Pre-tax Income
-66.49MUSDFY2025 · Dec 31, 2025Net Income
-66.49MUSDFY2025 · Dec 31, 2025EBIT
-72.84MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-71.37MUSDFY2025 · Dec 31, 2025Research & Development
55.97MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
16.87MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
6.40MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-66.49MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-57.68MUSDFY2025 · Dec 31, 2025Free Cash Flow
-57.71MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
31.21MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-66.49MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.47MUSDFY2025 · Dec 31, 2025Stock-based Compensation
8.37MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-664.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-369.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-25.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-194.56MUSDFY2025 · Dec 31, 2025Sale of Investments
101.28MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-93.31MUSDFY2025 · Dec 31, 2025Other Financing Charges
-9.66MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
128.33MUSDFY2025 · Dec 31, 2025Shares Outstanding
180.09MSharesUpdated Sep 26, 2026Float Shares
132.45MSharesUpdated Sep 26, 2026Shares Short
41.65MSharesUpdated Sep 26, 2026Short Ratio
16.67daysvs all stocks
Short % of Shares Outstanding
27.65%vs all stocks
% Held by Insiders
12.46%vs all stocks
% Held by Institutions
88.48%vs all stocks
Total Cash (MRQ)
179.88MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.9990USDUpdated Sep 26, 2026Total Debt (MRQ)
9.63MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0580xvs Biotechnology peers
Current Ratio (MRQ)
11.22xvs Biotechnology peers
Book Value per Share (MRQ)
0.9220USDUpdated Sep 26, 2026Total Assets
219.59MUSDvs all stocks (USD)
Total Current Assets
209.82MUSDFY2025 · Dec 31, 2025Total Liabilities
22.80MUSDFY2025 · Dec 31, 2025Total Non-current Assets
9.77MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
8.83MUSDFY2025 · Dec 31, 2025Total Current Liabilities
13.97MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
30.64MUSDFY2025 · Dec 31, 2025Other Short-term Investments
178.26MUSDFY2025 · Dec 31, 2025Accounts Payable
1.58MUSDFY2025 · Dec 31, 2025Short-term Debt
1.00MUSDFY2025 · Dec 31, 2025Long-term Debt
8.83MUSDFY2025 · Dec 31, 2025Common Stock (Book)
18.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-431.17MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
196.79MUSDvs all stocks (USD)
52-Week Low
1.10USDUpdated Sep 26, 202652-Week High
6.88USDUpdated Sep 26, 202652-Week Change
-70.42%vs all stocks
Beta
0.8450xvs all stocks
50-Day MA
2.10USDUpdated Sep 26, 2026200-Day MA
3.75USDUpdated Sep 26, 2026Avg 10-Day Volume
6.36MSharesUpdated Sep 26, 2026Avg 30-Day Volume
3.76MSharesUpdated Sep 26, 2026Diluted EPS (TTM)
-0.3900USDUpdated Sep 26, 2026Other Income / Expense
-50.00KUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 2.58: grey zoneSignificant
Altman Z-Score: 2.58
Low earnings qualitySignificant
Earnings Quality Score: -0.67
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $203.5M, lower than 95% of all stocks globallySignificant
Market cap (USD): 203,499,343Global P5: 275,556,405.438
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
NextBioMedical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Humedix Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Foghorn Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Minerva Neurosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
ImmuneOncia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sillajen Inc.
Tier 1ProductionApproval-Gated PipelineRule
RxSight Inc.
Tier 1ProductionApproval-Gated PipelineRule
TaiGen Biopharmaceuticals Holdings Limited
Tier 1ProductionApproval-Gated PipelineRuleRisk
Genomictree Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Protara Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
ADC Therapeutics S.A.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown
Akebia Therapeutics Inc.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown
Invivyd Inc.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown